Who We Are

Titan is a specialty pharmaceuticals company that develops therapeutics for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura. The company's lead product is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction. The U.S. Food and Drug Administration approved Probuphine on May 26, 2016. Probuphine is the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single administration procedure.

Learn More

ProNeura™ is a Proprietary, Long-Term, Continuous Drug Delivery Platform

The ProNeura long-term, continuous drug delivery platform is ideal for treating chronic diseases for which maintaining non-fluctuating medication levels may offer advantages over other routes of administration.

Learn More About ProNeura

Product Pipeline

Probuphine®

for the treatment of Opioid Addiction

Market completed
Market completed
Market completed
Market completed
Market in progress
Preclinical Phase 1 Phase 2 Phase 3 Market
More About Probuphine®

Product Pipeline

Ropinirole Implant

for the treatment of Parkinson's Disease

Preclinical in progress
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical Phase 1 Phase 2 Phase 3 Market
More About Ropinirole Implant

Product Pipeline

T3 Implant

for the treatment of Hypothyroidism

Preclinical in progress
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical Phase 1 Phase 2 Phase 3 Market
More About T3 Implant

Intellectual Property

Titan has a broad intellectual property portfolio that protects the ProNeura drug delivery platform, with issued patents and patent applications covering formulations and methods related to the treatment of chronic diseases, including opioid addiction and Parkinson's disease.

View IP Portfolio

Strategic Alliances

Titan has extensive expertise in pharmaceutical product development and plans to pursue commercial partnerships at the appropriate time in the development cycle of its products, adding value to Titan in the short- and the long-term. In 2012, Titan licensed the commercial rights to Probuphine in the U.S. and Canada to Braeburn Pharmaceuticals, valued at over $200 million in milestone payments, excluding tiered royalties in the mid-teen to low twenty percent of net sales.

Read More About Strategic Alliances

Leadership

Titan Pharmaceuticals' executive team has more than 75 years of collective experience in the pharmaceutical industry.

View Management Team View Board of Directors

Latest News

July 2, 2018
Titan Pharmaceuticals Provides Update On Parkinson's Disease Clinical Development Program

SAN FRANCISCO, July 2, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that the independent Data Safety Monitoring Board ("DSMB") for the company's Phase 1/2 trial of its r

Read Press Release
May 30, 2018
Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence
May 15, 2018
Titan Pharmaceuticals Reports First Quarter 2018 Financial Results
View all Press Releases